Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […]
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […]
